ASP 3662

Drug Profile

ASP 3662

Alternative Names: ASP-3662

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator Astellas Pharma
  • Class Analgesics; Antidementias
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Diabetic neuropathies

Most Recent Events

  • 31 Jan 2017 Phase-II clinical trials in Alzheimer's disease in USA (PO) (Astellas Pharma pipeline, January 2017)
  • 26 Sep 2016 Updated pharmacodynamics data from preclinical studies in Diabetic neuropathies presented at the 16th World Congress of Pain-2016 (WCP-2016)
  • 03 Jun 2016 Astellas Pharma terminated a phase II trial for Diabetic neuropathies (In adults, In the elderly) in USA due to futility analysis (NCT02372578)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top